Evelo Biosciences Inc logo

EVLO - Evelo Biosciences Inc Share Price

$5.13 0.1  1.2%

Last Trade - 2:35pm

Sector
Healthcare
Size
Small Cap
Market Cap £182.4m
Enterprise Value £127.5m
Revenue £n/a
Position in Universe 3583rd / 6407
Bullish
Bearish
Unlock EVLO Revenue
Momentum
Relative Strength (%)
1m +20.6%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -38.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Evelo Biosciences Inc revenues was not reported. Net loss increased 6% to $43.7M. Higher net loss reflects Interest expense, net decrease from $951K (income) to $639K (expense), Research and development - Balancing increase of 4% to $30.5M (expense), Stock-based Compensation in R&D increase of 11% to $2.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

EVLO Revenue Unlock EVLO Revenue

Net Income

EVLO Net Income Unlock EVLO Revenue

Normalised EPS

EVLO Normalised EPS Unlock EVLO Revenue

PE Ratio Range

EVLO PE Ratio Range Unlock EVLO Revenue

Dividend Yield Range

EVLO Dividend Yield Range Unlock EVLO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
EVLO EPS Forecasts Unlock EVLO Revenue
Profile Summary

Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated May 6, 2014
Public Since May 9, 2018
No. of Shareholders: 33
No. of Employees: 98
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 46,136,643
Free Float (0.0%)
Eligible for
ISAs
SIPPs
EVLO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for EVLO
Upcoming Events for EVLO
Frequently Asked Questions for Evelo Biosciences Inc
What is the Evelo Biosciences Inc share price?

As of 2:35pm, shares in Evelo Biosciences Inc are trading at $5.13, giving the company a market capitalisation of £182.4m. This share price information is delayed by 15 minutes.

How has the Evelo Biosciences Inc share price performed this year?

Shares in Evelo Biosciences Inc are currently trading at $5.13 and the price has moved by -18.75% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Evelo Biosciences Inc price has moved by -26.67% over the past year.

What are the analyst and broker recommendations for Evelo Biosciences Inc?

Of the analysts with advisory recommendations for Evelo Biosciences Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Evelo Biosciences Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Evelo Biosciences Inc next release its financial results?

Evelo Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Evelo Biosciences Inc dividend yield?

Evelo Biosciences Inc does not currently pay a dividend.

Does Evelo Biosciences Inc pay a dividend?

Evelo Biosciences Inc does not currently pay a dividend.

When does Evelo Biosciences Inc next pay dividends?

Evelo Biosciences Inc does not currently pay a dividend.

How do I buy Evelo Biosciences Inc shares?

To buy shares in Evelo Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Evelo Biosciences Inc?

Shares in Evelo Biosciences Inc are currently trading at $5.13, giving the company a market capitalisation of £182.4m.

Where are Evelo Biosciences Inc shares listed? Where are Evelo Biosciences Inc shares listed?

Here are the trading details for Evelo Biosciences Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: EVLO
What kind of share is Evelo Biosciences Inc?

Based on an overall assessment of its quality, value and momentum, Evelo Biosciences Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Evelo Biosciences Inc share price forecast 2020?

Shares in Evelo Biosciences Inc are currently priced at $5.13. At that level they are trading at 90.73% discount to the analyst consensus target price of 0.00.

Analysts covering Evelo Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.23 for the next financial year.

How can I tell whether the Evelo Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evelo Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been 10.03%. At the current price of $5.13, shares in Evelo Biosciences Inc are trading at 11.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Evelo Biosciences Inc PE Ratio?

We were not able to find PE ratio data for Evelo Biosciences Inc.

Who are the key directors of Evelo Biosciences Inc?

Evelo Biosciences Inc's management team is headed by:

Balkrishan Gill - PRE
Mark Bodmer - CSO
Duncan McHale - OTH
Lord Ara Darzi - IND
David Epstein - CHM
Theodose Melas-Kyriazi - IND
David Perry - IND
Nancy Simonian - IND
Juan Andres - IND
Xiaoli Liu - CAO
Daniel Char - GCN
Who are the major shareholders of Evelo Biosciences Inc?

Here are the top five shareholders of Evelo Biosciences Inc based on the size of their shareholding:

Flagship Ventures Venture Capital
Percentage owned: 49.64% (22.9m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 9.86% (4.55m shares)
HarbourVest Partners, L.L.C. Private Equity
Percentage owned: 6.64% (3.06m shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 5.43% (2.51m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 4.28% (1.97m shares)
Similar to EVLO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.